118 related articles for article (PubMed ID: 25995651)
1. Opana(®) ER induced thrombotic thrombocytopenic purpura.
Kotbi N; Han B; Cheng D; Odom AE
Int Med Case Rep J; 2015; 8():97-8. PubMed ID: 25995651
[TBL] [Abstract][Full Text] [Related]
2. Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER.
Aseem F; Zamora BG; Kauffman L; Miller PJ; John VJ
Am J Ophthalmol Case Rep; 2018 Sep; 11():72-74. PubMed ID: 29998206
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(1):1-4. PubMed ID: 23302815
[TBL] [Abstract][Full Text] [Related]
4. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.
Kapila A; Chhabra L; Chaubey VK; Summers J
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24591390
[TBL] [Abstract][Full Text] [Related]
5. Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura.
Ban BH; Verma A; Tudor M; Sethi J
Oxf Med Case Reports; 2017 Jun; 2017(6):omx026. PubMed ID: 28580158
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER.
Thakur K; Agrawal V; Kass A; Dimarino LM; Dorion RP; Vadakara J
Case Rep Hematol; 2017; 2017():1623907. PubMed ID: 28607779
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.
Miller PJ; Farland AM; Knovich MA; Batt KM; Owen J
Am J Hematol; 2014 Jul; 89(7):695-7. PubMed ID: 24668845
[TBL] [Abstract][Full Text] [Related]
8. THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH OPANA ER INTRAVENOUS ABUSE A Case Report.
Jabr FI; Yu L
J Med Liban; 2016; 64(1):40-2. PubMed ID: 27169165
[TBL] [Abstract][Full Text] [Related]
9. Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.
Mehmood H; Khan M; Marwat A; Joshi M; Malhotra V
J Investig Med High Impact Case Rep; 2018; 6():2324709618756423. PubMed ID: 29435466
[TBL] [Abstract][Full Text] [Related]
10. Opana ER-induced thrombotic microangiopathy.
Lämmle B
Blood; 2017 Feb; 129(7):808-809. PubMed ID: 28209752
[No Abstract] [Full Text] [Related]
11. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
Al-Husban N; Al-Kuran O
J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343
[TBL] [Abstract][Full Text] [Related]
12. Resurgence of intravenous Opana as a cause of secondary thrombotic thrombocytopenic purpura.
Rane M; Aggarwal A; Banas E; Sharma A
Am J Emerg Med; 2014 Aug; 32(8):951.e3-4. PubMed ID: 24630802
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
Hale ME; Ahdieh H; Ma T; Rauck R;
J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: a case control study.
Merayo-Chalico J; Demichelis-Gómez R; Rajme-López S; Aparicio-Vera L; Barrera-Vargas A; Alcocer-Varela J; Gómez-Martín D
Thromb Res; 2014 Nov; 134(5):1020-7. PubMed ID: 25257921
[TBL] [Abstract][Full Text] [Related]
16. Systemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the Literature.
Abu-Hishmeh M; Sattar A; Zarlasht F; Ramadan M; Abdel-Rahman A; Hinson S; Hwang C
Am J Case Rep; 2016 Oct; 17():782-787. PubMed ID: 27777394
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic thrombocytopenic purpura in a patient with rheumatoid arthritis treated by plasmapheresis.
Kfoury Baz EM; Mahfouz RA; Masri AF
Ther Apher; 1999 Nov; 3(4):314-6. PubMed ID: 10608725
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura.
Lalmuanpuii J; Yalamanchili K; Fircanis S; Nelson JC
J Clin Apher; 2009; 24(1):18-20. PubMed ID: 19073012
[TBL] [Abstract][Full Text] [Related]
19. Case report: thrombotic thrombocytopenic purpura in a patient with polymyositis: therapeutic importance of early recognition and discussion of pathogenic mechanisms.
Ellingson TL; Wilske K; Aboulafia DM
Am J Med Sci; 1992 Jun; 303(6):407-10. PubMed ID: 1605172
[TBL] [Abstract][Full Text] [Related]
20. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
Bennett CL; Kim B; Zakarija A; Bandarenko N; Pandey DK; Buffie CG; McKoy JM; Tevar AD; Cursio JF; Yarnold PR; Kwaan HC; De Masi D; Sarode R; Raife TJ; Kiss JE; Raisch DW; Davidson C; Sadler JE; Ortel TL; Zheng XL; Kato S; Matsumoto M; Uemura M; Fujimura Y;
J Am Coll Cardiol; 2007 Sep; 50(12):1138-43. PubMed ID: 17868804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
